Cyclerion Therapeutics (NASDAQ:CYCN) Stock Price Down 8.1%

Cyclerion Therapeutics, Inc. (NASDAQ:CYCNGet Free Report) shares traded down 8.1% during trading on Tuesday . The stock traded as low as $2.75 and last traded at $2.85. 2,377 shares traded hands during trading, a decline of 43% from the average session volume of 4,197 shares. The stock had previously closed at $3.10.

Cyclerion Therapeutics Trading Up 5.2 %

The business’s 50-day moving average price is $3.01 and its 200-day moving average price is $2.93.

Cyclerion Therapeutics (NASDAQ:CYCNGet Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.53) EPS for the quarter.

Institutional Investors Weigh In On Cyclerion Therapeutics

An institutional investor recently raised its position in Cyclerion Therapeutics stock. Tyndall Capital Partners L P grew its holdings in Cyclerion Therapeutics, Inc. (NASDAQ:CYCNFree Report) by 11.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 164,429 shares of the company’s stock after acquiring an additional 16,717 shares during the period. Cyclerion Therapeutics comprises approximately 100.0% of Tyndall Capital Partners L P’s holdings, making the stock its biggest holding. Tyndall Capital Partners L P owned about 6.71% of Cyclerion Therapeutics worth $551,000 as of its most recent SEC filing. 75.62% of the stock is currently owned by hedge funds and other institutional investors.

About Cyclerion Therapeutics

(Get Free Report)

Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.

Recommended Stories

Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.